Hormone giới tính nội sinh và mối liên hệ với các yếu tố nguy cơ bệnh tim mạch ở phụ nữ sau mãn kinh

Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 1987, 114: 413–9. Carr MC. The emergence of the metabolic syndrome with the menopause. J Clin Endocrinol Metab 2003, 88: 2404–11. Rexrode KM, Manson JE, Lee I, et al. Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation 2003, 108: 1688–93. Ridker PM, Hennekens CH, Bruing JF, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342: 836–43. Sites CK, Toth MJ, Cushman M, et al. Menopause related differences in inflammation markers and their relationship to body fat distribution and insulin stimulated glucose disposal. Fertil Steril 2002, 77: 128–35. Pradhan AD, Mason JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease. Prospective analysis form the Women’s Health Initiative observational study. JAMA 2002, 288: 980–7. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Report Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adults treatment Panel III). JAMA 2001, 285: 2486–97. Kramer PR, Kramer SF, Guan G. 17 beta-estradiol regulates cytokine release through modulation of CD16 expression in monocytes and monocyte-derived macrophages. Arthritis Rheum 2004, 50: 1967–75. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003, 88: 2470–8. Wassel CL, Barrett-Connor E, Laughlin GA. Association of circulating C-reactive protein and interleukin-6 with longetivity into the 80s and 90s: The Rancho Bernardo Study. J Clin Endocrinol Metab 2010, 95: 4748–55. Lacut K, Oger E, Le Gal G, et al. SARAH Investigators. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost 2003, 90: 124–31. Cooper BC, Burger NZ, Toth MJ, Cushman M, Sites CK. Insulin resistance with hormone replacement therapy: associations with markers of inflammation and adiposity. Am J Obstet Gynecol 2007, 196: 1–7. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998, 83: 847–50. Singh U, Dasu MR, Yancey PG, Afify A, Devaraj S, Jialal I. Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. J Lipid Res 2008, 49: 1015–23. Blum CA, Müller B, Huber P, et al. Low-grade inflammation and estimates of insulin resistance during the menstrual cycle in lean and overweight women. J Clin Endocrinol Metab 2005, 90: 3230–5. Störk S, Bots ML, Grobbee DE, van der Schouw YT. Endogenous sex hormones and C reactive protein in healthy postmenopausal women. J Intern Med 2008, 264: 245–53. Maggio M, Ceda GP, Lauretani F, et al. SHBG, Sex hormones, and inflammatory markers in older women. J Clin Endocrinol Metab 2011, 96: 1053–9. Karim R, Stanczyk FZ, Hodis HN, et al. Associations between markers of inflammation and physiological and pharmacological levels of circulating sex hormones in postmenopausal women. Menopause 2010, 17: 785–90. Yesilova Z, Ozata M, Kocar IH, et al. The effects of gonadotropin treatment on the immunological features of male patients with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2000, 85: 66–70. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 2002, 87: 3632–9. Kocoska-Maras L, Hirschberg AL, Byström B, Schoultz BV, Rådestad AF. Testosterone addition to estrogen therapy — effects on inflammatory markers for cardiovascular disease. Gynecol Endocrinol 2009, 25: 823–7. Philips GB, Pinkernell BH, Jing TY. Relationship between serum sex hormones and coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol 1997, 17: 695–701. Golden SH, Maguire A, Ding J, et al. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. Am J Epidemiol 2002, 155: 437–45. Bernini GP, Sgro’ M, Moretti A, et al. Endogenous androgens and carotid intimal-medial thickness in women. J Clin Endocrinol Metab 1999, 84: 2008–12. Joffe HV, Ridker PM, Manson JE, Cook NR, Buring JE, Rexrode KM. Sex hormone-binding globulin and serum testosterone are inversely associated with C-reactive protein levels in postmenopausal women at high risk for cardiovascular disease. Ann Epidemiol 2006, 16: 105–12. Crandall C, Palla S, Reboussin B, et al. Cross-sectional association between markers of inflammation and serum sex steroid levels in the postmenopausal estrogen/progestin interventions trial. J Womens Health (Larchmt) 2006, 15: 14–23. Maturana MA, Breda V, Lhullier F, Spitzer PM. Relationship between endogenous testosterone and cardiovascular risk in early postmenopausal women. Metabolism 2008, 57: 961–5. Hsu SC, Liu CM, Long CY, Yang CH, Lee JN, Tsai EM. Effect of oral conjugated equine estrogen combined with medroxyprogesterone acetate on plasma homocysteine levels in postmenopausal women. Fertil Steril 2005, 84: 1037–9. Christodoulakos GE, Lambrinoudaki IV, Rizos DA, Alexandrou A, Kountouris AV, Creatsas GC. Endogenous sex steroids and circulating homocysteine in healthy Greek postmenopausal women. Hormones (Athens) 2006, 5: 35–41. Bedranek-Tupikowska G, Tupikowski K, Bohdanowicz-Pawlak A, et al. Evaluation of the influence of sex hormones on homocysteine concentration in pre- and postmenopausal women. Pol Merkur Lekarski 2005, 18: 189–91. Weinberg ME, Manson JE, Buring JE, et al. Low sex hormone binding globulin is associated with the metabolic syndrome in postmenopausal women. Metabolism 2006, 55: 1473–80. Korhonen S, Hippelainen M, Vanhala M, Heinonen S, Niskanen L. The androgenic sex hormone profile is an essential feature of metabolic syndrome in premenopausal women: a controlled community-based study. Fertil Steril 2003, 79: 1327–34. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and metaanalysis. JAMA 2006, 295: 1288–99. Golden SH, Ding J, Szklo M, Schmidt MI, Duncan BB, Dobs A. Glucose and insulin components of the metabolic syndrome are associated with hyperandrogenism in postmenopausal women: the atherosclerosis risk in communities study. Am J Epidemiol 2004, 160: 540–8. Larsson H, Ahren B. Androgen activity as a risk factor for impaired glucose tolerance in postmenopausal women. Diabetes Care 1996, 19: 1399–403. DeNino WF, Tchernof A, Dionne IJ, et al. Contribution of abdominal adiposity to age-related differences in insulin sensitivity and plasma lipids in healthy nonobese women. Diabetes Care 2001, 24: 925–32. Sowers MF, Zheng H, Tomey K, et al. Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab 2007, 92: 895–901.